肝细胞癌
医学
纳米载体
恶性肿瘤
外体
靶向治疗
癌症
癌症研究
疾病
肿瘤科
内科学
生物信息学
微泡
药理学
药品
小RNA
生物
基因
生物化学
作者
Xiang Lin,Yu-Ting Tang,Lü Li,Xufeng Tao
标识
DOI:10.1016/j.abb.2023.109699
摘要
Hepatocellular carcinoma (HCC), which is a primary liver cancer subtype, has a poor prognosis due to its high degree of malignancy. The lack of early diagnosis makes systemic therapy the only hope for HCC patients with advanced disease; however, resistance to drugs is a major obstacle. In recent years, targeted molecular therapy has gained popularity as a potential treatment for HCC. An increase in reactive oxygen species (ROS), which are cancer markers and a potential target for HCC therapy, can both promote and inhibit the disease. At present, many studies have examined targeted regulation of ROS in the treatment of HCC. Here, we reviewed the latest drugs that are still in the experimental stage, including nanocarrier drugs, exosome drugs, antibody drugs, aptamer drugs and polysaccharide drugs, to provide new hope for the clinical treatment of HCC patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI